Last update June 30, 2022

N06BA09

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

It is a selective norepinephrine reuptake inhibitor used in the treatment of attention deficit hyperactivity disorder (ADHD). Oral administration once or twice daily.

On latest update relevant data on breastfeeding was not found.

Its high plasma protein binding and very wide volume of distribution make it highly unlikely that significant quantities will pass into breast milk.

No problems were seen in two infants whose mothers were taking it. (Besag 2014)

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.

Alternatives

  • Dexamfetamine Sulfate (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Methylphenidate (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

N06BA09 is Atomoxetine Hydrochloride in ATC Code/s.

Is written in other languages:

N06BA09 is also known as

Group

N06BA09 belongs to this group or family:

Tradenames

Main tradenames from several countries containing N06BA09 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 63 - 94 %
Molecular weight 292 daltons
Protein Binding 98 %
VD 0.85 l/Kg
Tmax 1 - 2 hours
T½ 3.6 - 21 hours

References

  1. Lilly. Atomoxetina (Strattera). Drug Summary. 2020 Full text (in our servers)
  2. AEMPS. Atomoxetina (Atamax). Ficha técnica. 2020 Full text (in our servers)
  3. Besag FM. ADHD treatment and pregnancy. Drug Saf. 2014 Jun;37(6):397-408. Abstract
  4. Cui YM, Teng CH, Pan AX, Yuen E, Yeo KP, Zhou Y, Zhao X, Long AJ, Bangs ME, Wise SD. Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele. Br J Clin Pharmacol. 2007 Abstract Full text (in our servers)
  5. Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005 Abstract

Total visits

648

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM